MX359574B - Alteraciones geneticas en isocitrato-deshidrogenasa y otros genes en glioma maligno. - Google Patents

Alteraciones geneticas en isocitrato-deshidrogenasa y otros genes en glioma maligno.

Info

Publication number
MX359574B
MX359574B MX2015015733A MX2015015733A MX359574B MX 359574 B MX359574 B MX 359574B MX 2015015733 A MX2015015733 A MX 2015015733A MX 2015015733 A MX2015015733 A MX 2015015733A MX 359574 B MX359574 B MX 359574B
Authority
MX
Mexico
Prior art keywords
isocitrate dehydrogenase
genes
genetic alterations
malignant glioma
mutations
Prior art date
Application number
MX2015015733A
Other languages
English (en)
Inventor
Vogelstein Bert
W Kinzler Kenneth
Williams Parsons D
Zhang Xiaosong
Cheng-Ho Lin Jimmy
J Leary Rebecca
Angenendt Philipp
Papadopoulos Nickolas
Velculescu Victor
Parmigiani Giovanni
Karchin Rachel
Jones Sian
Bigner Darell
Kuan Chien-Tsun
Riggins Gregory
Yan Hai
Original Assignee
Univ Johns Hopkins
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Johns Hopkins filed Critical Univ Johns Hopkins
Publication of MX359574B publication Critical patent/MX359574B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G16B40/20—Supervised data analysis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a un polipéptido mutante para usarse en el tratamiento de un tumor de GBM, en donde el polipéptido mutante comprende al menos 8 residuos contiguos de aminoácido de: una proteína de IDH1 humana en un tumor humano, los al menos 8 residuos contiguos de aminoácido que comprenden el residuo 132, en donde el residuo 132 no es arginina; o una proteína de IDH2 humana encontrada en un tumor humano, los a l menos 8 residuos contiguos de aminoácido que comprenden el residuo 172, en donde el residuo 172 no es arginina .
MX2015015733A 2008-09-03 2009-09-03 Alteraciones geneticas en isocitrato-deshidrogenasa y otros genes en glioma maligno. MX359574B (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US9373908P 2008-09-03 2008-09-03
US11039708P 2008-10-31 2008-10-31
US16273709P 2009-03-24 2009-03-24
PCT/US2009/055803 WO2010028099A1 (en) 2008-09-03 2009-09-03 Genetic alterations in isocitrate dehydrogenase and other genes in malignant glioma

Publications (1)

Publication Number Publication Date
MX359574B true MX359574B (es) 2018-10-03

Family

ID=41228200

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2012012788A MX343226B (es) 2008-09-03 2009-09-03 Alteraciones geneticas en isocitrato-deshidrogenasa y otros genes en glioma maligno.
MX2011002409A MX2011002409A (es) 2008-09-03 2009-09-03 Alteraciones geneticas en isocitrato-deshidrogenasa y otros genes en glioma maligno.
MX2015015733A MX359574B (es) 2008-09-03 2009-09-03 Alteraciones geneticas en isocitrato-deshidrogenasa y otros genes en glioma maligno.

Family Applications Before (2)

Application Number Title Priority Date Filing Date
MX2012012788A MX343226B (es) 2008-09-03 2009-09-03 Alteraciones geneticas en isocitrato-deshidrogenasa y otros genes en glioma maligno.
MX2011002409A MX2011002409A (es) 2008-09-03 2009-09-03 Alteraciones geneticas en isocitrato-deshidrogenasa y otros genes en glioma maligno.

Country Status (11)

Country Link
US (7) US8685660B2 (es)
EP (4) EP2546365B1 (es)
JP (3) JP5421374B2 (es)
CN (1) CN102177251B (es)
AU (1) AU2009288004B2 (es)
CA (1) CA2736125C (es)
DK (2) DK2326735T3 (es)
ES (3) ES2609414T3 (es)
MX (3) MX343226B (es)
PL (2) PL2326735T3 (es)
WO (1) WO2010028099A1 (es)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102177251B (zh) 2008-09-03 2017-06-16 约翰·霍普金斯大学 恶性神经胶质瘤的异柠檬酸脱氢酶和其他基因的遗传改变
MX346801B (es) * 2009-03-13 2017-03-31 Agios Pharmaceuticals Inc Métodos y composiciones para trastornos relacionados con la proliferación celular.
EP2253716A1 (en) 2009-05-15 2010-11-24 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Diagnostic methods for the prognosis of a brain tumor
KR101850813B1 (ko) 2009-06-29 2018-04-20 아지오스 파마슈티컬스 아이엔씨. 치료용 화합물 및 조성물
US8642271B2 (en) * 2009-08-27 2014-02-04 Case Western Reserve University Aberrant methylation of C6Orf150 DNA sequences in human colorectal cancer
WO2011031877A1 (en) 2009-09-09 2011-03-17 The General Hospital Corporation Use of microvesicles in analyzing nucleic acid profiles
WO2011031892A1 (en) 2009-09-09 2011-03-17 The General Hospital Corporation Use of microvesicles in analyzing kras mutations
ES2594402T3 (es) 2009-10-21 2016-12-20 Agios Pharmaceuticals, Inc. Métodos y composiciones para trastornos relacionados con la proliferación celular
EP2525790B1 (en) 2009-10-21 2020-05-27 Agios Pharmaceuticals, Inc. Methods and compositions for cell-proliferation-related disorders
EP2330218A1 (en) * 2009-12-07 2011-06-08 Europath Biosciences, S.L. EGFR and PTEN gene alterations predicts survival in patients with brain tumors
WO2012009678A1 (en) * 2010-07-16 2012-01-19 Agios Pharmaceuticals, Inc. Therapeutically active compositions and their method of use
US20140045915A1 (en) 2010-08-31 2014-02-13 The General Hospital Corporation Cancer-related biological materials in microvesicles
WO2012051622A2 (en) * 2010-10-15 2012-04-19 The General Hospital Corporation Microvesicle-based assays
WO2012054915A2 (en) * 2010-10-22 2012-04-26 Duke University Homozygous and heterozygous idh1 gene-defective human astrocytoma cell lines
US9074221B2 (en) 2010-10-25 2015-07-07 Duke University Homozygous and heterozygous IDH1 gene-defective cell lines derived from human colorectal cells
WO2012064993A1 (en) 2010-11-10 2012-05-18 Exosome Diagnosties, Inc. Method for isolation of nucleic acid containing particles and extraction of nucleic acids therefrom
CN110016499B (zh) 2011-04-15 2023-11-14 约翰·霍普金斯大学 安全测序系统
ME03074B (me) 2011-05-03 2019-01-20 Agios Pharmaceuticals Inc Akтivatori piruvat kinaze za upotrebu u terapiji
AU2012268619B2 (en) * 2011-06-06 2017-08-17 Sirna Therapeutics, Inc. RNA interference mediated inhibition of isocitrate dehydrogenase (IDH1) gene expression
CN102827073A (zh) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
CN102827170A (zh) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
WO2012176651A1 (ja) * 2011-06-22 2012-12-27 国立大学法人 京都大学 新規抗腫瘍剤及び新規抗腫瘍剤のスクリーニング方法
AU2012284100B2 (en) 2011-07-19 2016-12-15 Duke University Oligodendroglioma driver genes
US20130123335A1 (en) * 2011-09-12 2013-05-16 Mayo Foundation For Medical Education And Research Idh1 and idh2 mutations in cholangiocarcinoma
US10161940B2 (en) * 2012-01-05 2018-12-25 Deutsches Krebsforschungszentrum Means and methods for treating or diagnosing IDH1 R132H mutant-positive cancers
HUE038403T2 (hu) 2012-01-06 2018-10-29 Agios Pharmaceuticals Inc Terápiásan alkalmazható vegyületek és alkalmazási módszereik
US9474779B2 (en) 2012-01-19 2016-10-25 Agios Pharmaceuticals, Inc. Therapeutically active compositions and their methods of use
CN102732633B (zh) * 2012-07-06 2014-02-26 广州好芝生物科技有限公司 人idh基因突变的检测引物和试剂盒
AU2013331626B2 (en) 2012-10-15 2018-08-02 Agios Pharmaceuticals, Inc. Therapeutic compounds and compositions
CN104956225B (zh) 2012-10-29 2018-10-02 约翰·霍普金斯大学 卵巢和子宫内膜癌的帕帕尼科拉乌测试
US20160312311A1 (en) * 2013-03-12 2016-10-27 Novartis Ag Markers for isocitrate dehydrogenase inhibitors
EP3004396B1 (en) 2013-06-06 2019-10-16 The General Hospital Corporation Compositions for the treatment of cancer
WO2015003355A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
US9579324B2 (en) 2013-07-11 2017-02-28 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
WO2015003360A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
CA2917671A1 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. 2,4-or 4,6-diaminopyrimidine compounds as idh2 mutants inhibitors for the treatment of cancer
US20150031627A1 (en) 2013-07-25 2015-01-29 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
CN103451314A (zh) * 2013-09-30 2013-12-18 南京艾迪康医学检验所有限公司 检测idh1、idh2基因多态突变位点的引物、方法和试剂盒
WO2015116530A1 (en) * 2014-01-28 2015-08-06 Duke University Mutatations define clinical subgroups of gliomas
US9968595B2 (en) 2014-03-14 2018-05-15 Agios Pharmaceuticals, Inc. Pharmaceutical compositions of therapeutically active compounds
KR102278401B1 (ko) * 2014-08-25 2021-07-19 듀크 유니버시티 빈발 돌연변이의 신속도 및 민감도 검출 방법
WO2016106391A1 (en) * 2014-12-22 2016-06-30 The Broad Institute, Inc. Rapid quantitative detection of single nucleotide polymorphisms or somatic variants and methods to identify malignant neoplasms
US20180087114A1 (en) * 2015-03-05 2018-03-29 Trovagene, Inc. Early assessment of mechanism of action and efficacy of anti-cancer therapies using molecular markers in bodily fluid
JP7320339B2 (ja) 2015-06-11 2023-08-03 アジオス ファーマシューティカルズ， インコーポレイテッド ピルビン酸キナーゼ活性化因子を使用する方法
US11286531B2 (en) 2015-08-11 2022-03-29 The Johns Hopkins University Assaying ovarian cyst fluid
CN105112545A (zh) * 2015-09-23 2015-12-02 北京泛生子生物科技有限公司 检测人类idh1基因突变的方法及其试剂盒
MX2018004587A (es) 2015-10-15 2018-08-14 Agios Pharmaceuticals Inc Terapia de combinacion para tratar tumores malignos.
KR20180067658A (ko) 2015-10-15 2018-06-20 아지오스 파마슈티컬스 아이엔씨. 악성 종양의 치료를 위한 조합물 요법
CN105675868A (zh) * 2016-01-15 2016-06-15 江涛 基于idh1-r132h和atrx表达的胶质瘤分型系统
US20170273926A1 (en) * 2016-03-24 2017-09-28 Orbus Therapeutics, Inc. Compositions and methods for use of eflornithine and derivatives and analogs thereof to treat cancers, including gliomas
CN107556366A (zh) * 2016-06-30 2018-01-09 上海海和药物研究开发有限公司 具有突变型异柠檬酸脱氢酶抑制活性的化合物、其制备方法及用途
EP3523274A4 (en) 2016-10-06 2020-05-13 Orbus Therapeutics, Inc. FORMULATIONS FOR THE ADMINISTRATION OF EFLORNITHIN
CN106957367B (zh) * 2017-03-31 2020-02-21 北京爱仁医疗科技有限公司 抗idh1 r132h抗体及其制备方法和用途
WO2018213296A1 (en) * 2017-05-15 2018-11-22 Fred Hutchinson Cancer Research Center Genetic panel to molecularly classify diffuse gliomas
AU2018338975A1 (en) * 2017-09-28 2020-04-16 Gavish-Galilee Bio Applications Ltd. A universal platform for preparing an inhibitory chimeric antigen receptor (iCAR)
US20210363588A1 (en) * 2018-03-09 2021-11-25 Duke University Addressing Treatments for Glioblastoma
CN108315432A (zh) * 2018-05-04 2018-07-24 良培基因生物科技（武汉）有限公司 ddPCR技术检测IDH1 R132C基因变异的引物、试剂盒及检测方法
CN108384857A (zh) * 2018-05-04 2018-08-10 良培基因生物科技（武汉）有限公司 ddPCR技术检测IDH1 R132H基因变异的引物、试剂盒及检测方法
US11013733B2 (en) 2018-05-16 2021-05-25 Forma Therapeutics, Inc. Inhibiting mutant isocitrate dehydrogenase 1 (mlDH-1)
US11311527B2 (en) 2018-05-16 2022-04-26 Forma Therapeutics, Inc. Inhibiting mutant isocitrate dehydrogenase 1 (mIDH-1)
US10532047B2 (en) 2018-05-16 2020-01-14 Forma Therapeutics, Inc. Solid forms of ((S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile
US11013734B2 (en) 2018-05-16 2021-05-25 Forma Therapeutics, Inc. Treating patients harboring an isocitrate dehydrogenase-1 (IDH-1) mutation
WO2019222553A1 (en) 2018-05-16 2019-11-21 Forma Therapeutics, Inc. Inhibiting mutant idh-1
CN108588194A (zh) * 2018-05-28 2018-09-28 北京诺禾致源科技股份有限公司 利用高通量测序数据检测肿瘤突变负荷的方法及装置
US10980788B2 (en) 2018-06-08 2021-04-20 Agios Pharmaceuticals, Inc. Therapy for treating malignancies
US11311538B2 (en) 2018-07-13 2022-04-26 Yale University Compositions and methods for targeting cancers
TW202043256A (zh) 2019-01-10 2020-12-01 美商健生生物科技公司 前列腺新抗原及其用途
KR102203850B1 (ko) * 2019-04-09 2021-01-18 사회복지법인 삼성생명공익재단 신경교종의 진단 또는 예후 예측용 조성물 및 이에 관한 정보를 제공하는 방법
CN110646557A (zh) * 2019-10-12 2020-01-03 北京航空航天大学 携带idh基因突变的胶质母细胞瘤患者的尿液代谢标志物及其用途
CN112071365B (zh) * 2020-09-17 2023-09-19 北京理工大学 基于pten基因状态筛选胶质瘤生物标记物的方法
CN114381522B (zh) * 2021-12-30 2023-09-05 南京医科大学 Nup98基因作为胶质瘤干细胞特异性分子标志物和胶质母细胞瘤治疗及预后靶点的应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5556747A (en) * 1990-07-09 1996-09-17 E. R. Squibb & Sons, Inc. Method for site-directed mutagenesis
JPH11116479A (ja) * 1997-10-10 1999-04-27 Sugen Inc 脳癌のための組み合わせ化学療法処置
DE19817948A1 (de) * 1998-04-17 1999-10-21 Metagen Gesellschaft Fuer Genomforschung Mbh Menschliche Nukleinsäuresequenzen aus Endometrium-Tumor
WO2000052165A2 (en) * 1999-03-04 2000-09-08 Corixa Corporation Compositions and methods for breast cancer therapy and diagnosis
EP1392861A1 (en) * 2001-02-27 2004-03-03 EOS Biotechnology, Inc. Novel methods of diagnosis of metastatic colorectal cancer, compositions and methods of screening for modulators of metastatic colorectal cancer
WO2003082331A1 (fr) * 2002-03-29 2003-10-09 Anges Mg, Inc. Compositions de leurre destinees au traitement et a la prevention de maladies et de pathologies cerebrales
US20040067234A1 (en) 2002-07-11 2004-04-08 Paz Einat Isocitrate dehydrogenase and uses thereof
AU2003287564A1 (en) 2002-11-04 2004-06-07 Howard Hughes Medical Institute Methods of detecting colorectal cancer
DE102004037860A1 (de) 2004-08-04 2006-03-16 Friedrich-Alexander-Universität Erlangen-Nürnberg Turmormarker zur Diagnose von Karzinomen und/oder davon abstammender Metastasen
JP2006300758A (ja) * 2005-04-21 2006-11-02 Apro Life Science Institute Inc 内部標準ペプチドを用いて生体由来試料に含まれる標的タンパク質を定量する方法
JP2006325524A (ja) * 2005-05-27 2006-12-07 Institute Of Physical & Chemical Research 神経幹細胞及び脳神経疾患のためのマーカー
WO2008018789A2 (en) * 2006-08-08 2008-02-14 Leiden University Medical Center Methods and means for diagnosing and treatment of osteoarthritis
US20080108061A1 (en) * 2006-11-02 2008-05-08 Johji Inazawa Method for detecting cancer and a method for suppressing cancer
CN102177251B (zh) 2008-09-03 2017-06-16 约翰·霍普金斯大学 恶性神经胶质瘤的异柠檬酸脱氢酶和其他基因的遗传改变
MX346801B (es) 2009-03-13 2017-03-31 Agios Pharmaceuticals Inc Métodos y composiciones para trastornos relacionados con la proliferación celular.
EP2253716A1 (en) 2009-05-15 2010-11-24 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Diagnostic methods for the prognosis of a brain tumor

Also Published As

Publication number Publication date
EP2607498A1 (en) 2013-06-26
EP2546365B1 (en) 2016-11-09
US10704108B2 (en) 2020-07-07
EP2546365A1 (en) 2013-01-16
AU2009288004A1 (en) 2010-03-11
ES2609414T3 (es) 2017-04-20
US20120202207A1 (en) 2012-08-09
CA2736125C (en) 2019-04-09
EP2326735B1 (en) 2016-11-16
PL2546365T3 (pl) 2017-07-31
US9353418B2 (en) 2016-05-31
US20140187764A1 (en) 2014-07-03
ES2608310T3 (es) 2017-04-07
US20170081730A1 (en) 2017-03-23
EP3266879A1 (en) 2018-01-10
WO2010028099A1 (en) 2010-03-11
MX343226B (es) 2016-10-28
DK2546365T3 (en) 2017-01-16
US20190106752A1 (en) 2019-04-11
US10837064B2 (en) 2020-11-17
JP2014110786A (ja) 2014-06-19
AU2009288004B2 (en) 2015-02-05
US20210317532A1 (en) 2021-10-14
EP2326735A1 (en) 2011-06-01
PL2326735T3 (pl) 2017-04-28
EP3266879B1 (en) 2019-07-03
JP6016755B2 (ja) 2016-10-26
US20110229479A1 (en) 2011-09-22
CA2736125A1 (en) 2010-03-11
MX2011002409A (es) 2011-09-06
CN102177251A (zh) 2011-09-07
US20180282821A1 (en) 2018-10-04
DK2326735T3 (en) 2017-01-16
EP2607498B1 (en) 2017-05-03
CN102177251B (zh) 2017-06-16
JP2012501652A (ja) 2012-01-26
JP2016129517A (ja) 2016-07-21
US10894987B2 (en) 2021-01-19
ES2755139T3 (es) 2020-04-21
US8685660B2 (en) 2014-04-01
JP5421374B2 (ja) 2014-02-19

Similar Documents

Publication Publication Date Title
MX343226B (es) Alteraciones geneticas en isocitrato-deshidrogenasa y otros genes en glioma maligno.
Di Stefano et al. Detection, characterization, and inhibition of FGFR–TACC fusions in IDH wild-type glioma
Kimura et al. Detection of epidermal growth factor receptor mutations in serum as a predictor of the response to gefitinib in patients with non–small-cell lung cancer
Goeppert et al. BRAF V600E-specific immunohistochemistry reveals low mutation rates in biliary tract cancer and restriction to intrahepatic cholangiocarcinoma
Kuhn et al. Frequent CCNE1 amplification in endometrial intraepithelial carcinoma and uterine serous carcinoma
Italiano et al. Clinical and biological significance of CDK4 amplification in well-differentiated and dedifferentiated liposarcomas
Oberholzer et al. RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors
EP2837697A3 (en) Prostate cancer-specific alterations in ERG gene expression and detection and treatment methods based on those alternations
Cankovic et al. The role of MGMT testing in clinical practice: a report of the association for molecular pathology
Xu et al. Epigenetic inactivation of BCL6B, a novel functional tumour suppressor for gastric cancer, is associated with poor survival
Varona et al. Altered levels of acid, basic, and neutral peptidase activity and expression in human clear cell renal cell carcinoma
Lee et al. Giant cell tumor of soft tissue is genetically distinct from its bone counterpart
Jhaveri et al. Glomerular diseases associated with cancer, chemotherapy, and hematopoietic stem cell transplantation
WO2007112330A3 (en) Compositions and methods for detection, prognosis and treatment of colon cancer
EP2518509A3 (en) Molecular prognosis and classification of malignant melanoma based upon markers selected from the list consisting of RGS1, NCOA3, SPP1, PHIP.
Wang et al. Progression of EGFR-mutant lung adenocarcinoma is driven by alveolar macrophages
EP2611941A4 (en) GENESIS OF CANCER DIAGNOSIS AND PROGNOSIS
Kazmi et al. Prognostic significance of K-ras codon 12 mutation in patients with resected gallbladder cancer
Panero et al. Expression profile of shelterin components in plasma cell disorders. Clinical significance of POT1 overexpression
Huang et al. Anti-apoptotic signature in thymic squamous cell carcinomas–functional relevance of anti-apoptotic BIRC3 expression in the thymic carcinoma cell line 1889c
Hartmann et al. Macrophages in T cell/histiocyte rich large B cell lymphoma strongly express metal‐binding proteins and show a bi‐activated phenotype
Zhang et al. Selective inhibition of the second bromodomain of BET family proteins results in robust antitumor activity in preclinical models of acute myeloid leukemia
Ryan et al. Delivery of personalized care for locally advanced rectal cancer: incorporating pathological, molecular genetic, and immunological biomarkers into the multimodal paradigm
Lingohr et al. Clinicopathological, immune and molecular correlates of PD-L2 methylation in gastric adenocarcinomas
Martin et al. Immunologic biomarkers and biomarkers for immunotherapies in gastrointestinal cancer